4.3 Article

Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia

Journal

PHARMACOLOGY RESEARCH & PERSPECTIVES
Volume 9, Issue 3, Pages -

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1002/prp2.755

Keywords

ATP; Drp1; Drp1-dependent small peptides; frataxin; Friedreich ataxia; mitochondrial fragmentation; mitochondrial homeostasis

Funding

  1. MDA Research Grant [MDA515617]
  2. FARA Center of Excellence
  3. FARA Research Grant

Ask authors/readers for more resources

Friedreich ataxia is a neurodegenerative disease characterized by the lack of frataxin protein in mitochondria. Deficiency of frataxin leads to excessive mitochondrial fragmentation, partially dependent on Drp1 activity. Inhibiting Drp1 can reverse mitochondrial fragmentation.
Friedreich ataxia is an autosomal recessive, neurodegenerative disease characterized by the deficiency of the iron-sulfur cluster assembly protein frataxin. Loss of this protein impairs mitochondrial function. Mitochondria alter their morphology in response to various stresses; however, such alterations to morphology may be homeostatic or maladaptive depending upon the tissue and disease state. Numerous neurodegenerative diseases exhibit excessive mitochondrial fragmentation, and reversing this phenotype improves bioenergetics for diseases in which mitochondrial dysfunction is a secondary feature of the disease. This paper demonstrates that frataxin deficiency causes excessive mitochondrial fragmentation that is dependent upon Drp1 activity in Friedreich ataxia cellular models. Drp1 inhibition by the small peptide TAT-P110 reverses mitochondrial fragmentation but also decreases ATP levels in frataxin-knockdown fibroblasts and FRDA patient fibroblasts, suggesting that fragmentation may provide a homeostatic pathway for maintaining cellular ATP levels. The cardiolipin-stabilizing compound SS-31 similarly reverses fragmentation through a Drp1-dependent mechanism, but it does not affect ATP levels. The combination of TAT-P110 and SS-31 does not affect FRDA patient fibroblasts differently from SS-31 alone, suggesting that the two drugs act through the same pathway but differ in their ability to alter mitochondrial homeostasis. In approaching potential therapeutic strategies for FRDA, an important criterion for compounds that improve bioenergetics should be to do so without impairing the homeostatic response of mitochondrial fragmentation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available